Frontlight ResearchEarly access
CompletedNo phase
Assessment of Vivity With French Clinical Data Related to the Toric Model Study
Key facts
- Who runs it
- Versailles Hospital
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 31 people enrolled
- Started
- 9 Sept 2022
- Ended
- 12 Jul 2024
- Type of study
- Observational
- Record updated
- 1 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patient presenting for a request for cataract surgery in current practice: phacoemulsification followed by classic implantation of an IOL with small incision size (< 2.2mm)
- Calculated power of IOL is between 10.0 and 30.0 diopters (D) in 0.5D steps to target emmetropia (0.0 +/- 0.5D)
- Patients with corneal astigmatism > 0.5D and who can receive an implant with a toricity between T2 and T6, i.e. with astigmatism between +0.5D and +2.5D
- If both eyes have astigmatism, the eye under study will be the right eye
- Patient having been informed and not objecting to their participation
Who cannot take part
- Patient at risk of zonular rupture during the phacoemulsification procedure and may affect the centering or tilt of the implant postoperatively
- Any other planned eye surgery
- History of pathologies of the anterior segment of the eye (cornea, anterior chamber, sulcus) or posterior segment of the eye (uvea, vitreous, retina) including retinal vascular occlusions, retinal detachment, peripheral retinal laser photocoagulation, AMD and glaucoma
- Any inflammation of the anterior or posterior segment, whatever its etiology or history of disease, which may lead to an inflammatory reaction
- Clinically significant severe dry eye disease that may affect visual calculations and measurements
- History of refractive surgery
- Amblyopia or monofixation syndrome
- Person under the age of 18
- Pregnancy or breastfeeding while conducting the study
- Clinically significant corneal pathology (epithelial, stromal, or endothelial that could affect visual outcome)
- Irregular astigmatism (corneal topography)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Presbyopia-correcting implant (PC-IOL): AcrySof IQ Vivity (Alcon) has been evaluated in 2 large pivotal trials (US and OUS trials). These tests showed that this PC-IOL restored intermediate visual acuity (IVA) and near visual acuity (NV A) superior to that of the reference monofocal AcrySof implant. In these tests, it was demonstrated that distance visual acuity (DVA) was non-inferior. However, the intermediate visual acuity for this implant in its toric version has not been evaluated.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 October 2026